Document is current
Any future updates will be listed below
-
Authors
Wyszynski, Diego F. https://orcid.org/0000-0001-6293-3429
Bhattacharya, Mondira
Martínez-Pérez, Oscar
Scialli, Anthony R. https://orcid.org/0000-0003-1351-4572
Tassinari, Melissa
Bar-Zeev, Naor https://orcid.org/0000-0003-0570-4624
Renz, Cheryl https://orcid.org/0000-0002-7051-1653
Hernández-Díaz, Sonia https://orcid.org/0000-0003-1458-7642
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04705116 at ClinicalTrials.govDocuments that mention this clinical trial
The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER): Protocol and Methodological Considerations
https://doi.org/10.1007/s40264-022-01271-3
-
Funding
Funding for this research was provided by:
AstraZeneca
Janssen Pharmaceuticals
Sanofi Pasteur
Novavax
Valneva
- License Information
-
More Information
Article History
Accepted: 30 December 2022
First Online: 22 January 2023
Declarations
:
: The C-VIPER receives funding from AstraZeneca, Janssen, Novavax, Sanofi, and Valneva.
: Diego F. Wyszynski, Mondira Bhattacharya, Oscar Martínez-Pérez, Anthony R. Scialli, Melissa Tassinari, Naor Bar-Zeev, Cheryl Renz, and Sonia Hernández-Díaz have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: The C-VIPER study protocol may be made available by the corresponding author on reasonable request, following applicable regulations.
: Not applicable.
: The original study protocol was designed by DFW and SH-D. DFW planned the study, designed the study methodology, supervised data collection and data verification, and drafted the first version of the article. MB, OM, AS, MT, NB-Z, CR, and SH-D provided advice on the study methodology and edited the first and final versions of the article. All authors have read and approved the final version of the manuscript.
Free to read: This content has been made available to all.
